文献速递免疫规划

以革兰阳性基质(GEM)颗粒佐剂的鼻内季节性流感疫苗(FluGEM)在健康成人和老年人中的安全性、反应原性和免疫原性:一项随机、双盲、对照、剂量递增研究

Safety, reactogenicity and immunogenicity of an intranasal seasonal influenza vaccine adjuvanted with gram-positive matrix (GEM) particles (FluGEM): A randomized, double-blind, controlled, ascending dose study in healthy adults and elderly.
PubMed 文献 · Vaccine · 2024-05-20

鼻内FluGEM®安全且耐受良好,多数不良事件为轻度(97.4%),所有组几何平均增长≥2.5倍;1.25 mg和2.5 mg剂量免疫原性最高(相比5 mg),提示潜在非线性剂量-反应关系;老年人免疫原性较弱。

要点

  • 鼻内FluGEM®在18-49岁健康成人和65岁及以上老年人中安全且耐受良好。
  • 多数不良事件为轻度(97.4%),各剂量组和对照组不良事件相当。
  • 1.25 mg和2.5 mg剂量免疫原性最高(相比5 mg),提示潜在非线性剂量-反应关系。

核心结论

  • 鼻内接种FluGEM®在18-49岁健康成人志愿者和65岁及以上老年人中安全且可耐受。
  • 1.25 mg和2.5 mg剂量(相比5 mg)观察到最高免疫原性,提示潜在非线性剂量-反应关系。
  • 需要更多研究进一步探究细菌样肽作为佐剂的能力。

研究设计与样本

  • 首个人体、随机、双盲、对照、剂量递增研究,在荷兰人类药物研究中心(CHDR)开展。
  • 18-49岁参与者按3:1比例随机接受递增剂量FluGem®(两剂方案)联合标准三价灭活流感疫苗或仅接受无佐剂TIV。
  • 主要结局为安全性和耐受性,次要结局为血清血凝抑制(HI)抗体滴度和黏膜IgA。
  • 最具免疫原性的剂量用于额外的老年人队列(>65岁)。

主要发现

  • 鼻内FluGem®安全且耐受良好,大多数不良事件为轻度(97.4%),(非)征集性不良事件在所有剂量水平和对照组间相当。
  • 所有组显示几何平均增长≥2.5倍。
  • 1.25 mg剂量在第21天(单剂)和第42天(两剂)均达到血清转化(≥40%参与者),2.5 mg剂量仅在第42天(两剂)达到。
  • 第21天1.25 mg组观察到最高几何平均IgA增长。
  • 老年人免疫原性较弱。

关键数值与推荐

  • 血清转化定义为≥40%参与者达到。
  • 1.25 mg剂量在第21天(单剂)和第42天(两剂)达到血清转化。
  • 2.5 mg剂量仅在第42天(两剂)达到血清转化。
  • 所有组几何平均增长≥2.5倍。
  • 最高几何平均IgA增长见于第21天1.25 mg组。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 老年人免疫原性较弱。
  • 需要更多研究进一步探究细菌样肽作为佐剂的能力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intranasal administration of respiratory vaccines offers many advantages such as eliciting both systemic and mucosal immunity at the point of viral entry. Immunogenicity of intranasal vaccination can be improved through the use of adjuvants. Bacteria-like particles derived fromLactococcus lactishave the potential to serve as a vaccine adjuvant.This clinical study investigated the safety, reactogenicity and immunogenicity of intranasal seasonal influenza vaccine adjuvanted with gram-positive matrix particles (FluGEM®). METHODS: This was a first-in-human, randomized, double-blind, controlled, dose-escalation study performed at the Centre for Human Drug Research (CHDR), the Netherlands. Participants aged 18-49 were randomized in a 3:1 ratio to receive FluGem® in ascending doses (two-dose regimens) together with a standard trivalent inactivated influenza vaccine or unadjuvanted TIV only. Primary outcomes were safety and tolerability. Secondary outcomes were serum hemagglutination inhibition (HI) antibody titers and mucosal IgA. The most immunogenic dose was used in an additionalelderly cohort (>65 years). RESULTS: Ninty participants were included. Intranasal FluGem®was safe and well tolerated. The majority of adverse events were mild (97.4 %) with (un)solicited adverse events comparable across all dose levels and control groups. All groups showed geometric mean increases ≥ 2.5-fold. Seroconversion (≥40 % participants) was achieved at both day 21 (single-dose) and 42 (two-dose) for the 1.25 mg dose and on day 42 (two-dose only) for the 2.5 mg dose. Highest geometric mean IgA increases were observed in the 1.25 mg group on day 21. Immunogenicity was less pronounced in elderly. CONCLUSIONS: Intranasal vaccination of FluGEM®was safe and tolerable in healthy adult volunteers aged 18-49 years and 65 and older. Highest immunogenicity was observed for 1.25 mg and 2.5 mg doses (compared to 5 mg) suggesting a potential non-linear dose-response relationship.More research is needed to further investigate the capabilities of bacteria-like peptides as adjuvants.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. van der Plas JL, Haijema BJ, Leenhouts K, et al. Safety, reactogenicity and immunogenicity of an intranasal seasonal influenza vaccine adjuvanted with gram-positive matrix (GEM) particles (FluGEM): A randomized, double-blind, controlled, ascending dose study in healthy adults and elderly. Vaccine. 2024. PMID: 38772837. doi:10.1016/j.vaccine.2024.03.063

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。